Immunicon Corporation and its subsidiaries engage in the development, manufacture, marketing, and sale of proprietary cell-based diagnostic and research products, and services with a focus on cancer. It develops technologies that identify, count, and characterize a small number of circulating tumor cells (CTC) and other rare cells present in a blood sample of a patient.